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 Prescription drug abuse has been a growing problem in Indiana and around the nation for almost two 
decades. In recent years, prescription drug overdoses have pushed drug poisonings ahead of motor 
vehicle crashes as the leading cause of injury death. However, deaths due to overdoses of prescription 
drugs are only the tip of the iceberg when it comes to the much larger problem of abuse. This study 
has characterized prescription drug abuse in Indiana and taken an in-depth look at how it is and can 
be addressed both through organizational policies and state legislation. Opioid painkillers such as 
hydrocodone, oxycodone, and methadone are the most commonly abused prescription drugs, and 
most of these prescriptions are written by primary care physicians. Because more than 70% of 
Indiana’s family medicine residents will remain in the state to practice medicine following the 
conclusion of their residencies, it is worthwhile to take a look at how these residents are being 
educated during their training. St. Vincent’s Family Medicine Residency program in Indianapolis is one 
of several residency programs in Indiana training their residents on best practices of prescribing 
controlled substances. A review of residents’ prescribing patterns before and after training on the 
subject went into effect showed significant reductions in the number of opioid painkillers being 
prescribed, and showed the same reductions for alprazolam, a benzodiazepine anxiolytic. 
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Prescription drug abuse has been a growing problem in the United States in general, and in 
Indiana in particular, for almost two decades (CDC, 2011a). In recent years, drug poisonings, of 
which those due to prescription drugs make up a large proportion, have overtaken motor-vehicle 
crashes as the leading injury cause of death (NCHS, 2011). This increase in deaths due to 
prescription drug abuse corresponds to a 300% increase in sales of opioid painkillers since 1999 
(CDC, 2011a). 
Health care practitioners know that many types of drugs may by abused, and that the current 
trend is strongly toward abuse of prescription painkillers, with the most commonly abused 
painkillers being opioids such as hydrocodone, oxycodone, and methadone. These drugs are 
responsible for more deaths annually than cocaine and heroin combined (CDC, 2011a). Sadly, 
emergency department visits due to pharmaceutical misuse or abuse have more than doubled since 
2004 (SAMHSA, 2011a), and treatment admissions due to opiate abuse have more than quadrupled 
since 2000 (SAMHSA, 2011b) 
In Indiana, the number of unintentional poisoning deaths nearly doubled between 2006 and 
2009 (CDC, NCIPC, 2011b). The Youth Risk Behavior Survey (YRBS) tells us that greater than 
one in five Hoosier high-schoolers have misused prescription drugs without a doctor’s prescription 
(CDC, 2011b). Opiate withdrawal in newborn babies has skyrocketed, as well. Twelve years ago, 
the average hospital encountered neonatal abstinence syndrome (NAS) once a year. Now, the 
average hospital is seeing it every week (Winchester, 2012). Based on the 2008 National Survey 
on Drug Use and Health results, 6% of Hoosiers 12 years and older reported non-medical use of 
painkillers compared to 4.9% in the U.S. (IUCHP, 2009). This excess prescription drug abuse in 
Indiana is statistically significant (IUCHP, 2009) indicating that while prevention efforts are sorely 
needed across the nation, they are especially needed in Indiana. 
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We see almost 700 deaths due to accidental drug poisonings every year in this state alone, 
with the highest number of deaths as of 2010 occurring in Marion County (104), Allen County 
(33), Madison County (31), Vanderburgh County (25), and Porter County (24). With almost 6.5 
million people living in Indiana, that translates to more than 10 deaths due to accidental drug 
poisonings per 100,000 Hoosiers every year. Some of Indiana’s 92 counties are seeing rates 
significantly higher than that, though, with the highest number of deaths per 100,000 occurring in 
Starke County (38.52), Blackford County (27.42), Greene County (25.63), Scott County (24.82), 
and Henry County (24.26). Maps illustrating the annual death rates and the current trends in these 
rates are located in Figure 1 and Figure 2 (ISDH, 2012). 
While the number of deaths caused by abuse of these strong prescription painkillers is 
startling information all by itself, these deaths are only the tip of the iceberg when it comes to the 
larger epidemic of prescription drug abuse. Information provided by the CDC tells us that for every 
death from prescription painkiller abuse, there are 10 treatment admissions for painkiller abuse, 
32 emergency department visits for misuse or abuse, 130 people who abuse or are dependent on 
these drugs, and 825 recreational users of prescription painkillers (CDC, NCIPC, 2011a). 
Indiana’s Attorney General Gregory Zoeller formed the Prescription Drug Abuse Task 
Force, consisting of members of the public and private sectors from all parts of Indiana, in 2012 
to pursue solutions to the epidemic of prescription drug abuse while also making sure that patients 
for whom the benefits of prescription painkillers outweigh the very serious risks are able to receive 
the care they need. The Task Force has found many factors which may facilitate the problem. For 
example, improved law enforcement initiatives have been considered and undertaken by the Task 
Force’s Enforcement Committee. Better and more seamless use of  
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Figure 1: Annual Death Rates Due to Prescription Drug Abuse in Indiana  
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Figure 2: Trend in Annual Death Rates Due to Prescription Drug Abuse in Indiana  
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electronic medical records and prescription drug monitoring programs has been the work of the 
INSPECT Committee (INSPECT is Indiana’s prescription drug monitoring program). Helping and 
encouraging the public to safely dispose of excess prescription drugs, and keeping them from being 
diverted, has been the work of the Take-Back Committee, and initiatives aimed at treating those 
with existing addiction and dependency problems have been the work of the Treatment Committee. 
 The Education Committee, though, has pursued an often underappreciated fact: that for 
every abuser there is an initial exposure to prescription drugs. This initial exposure is typically the 
result of a well-meaning provider writing a prescription, and not from obtaining these drugs 
illegally (Juurlink, Dhalla, & Nelson, 2011). This initial drug exposure most likely reflects a desire 
for compassionate care and patient satisfaction on the part of the physician. 
 It is also worth noting that most opioid prescriptions are written by primary care physicians 
(Juurlink, Dhalla, & Nelson, 2011). Many providers, though, are beginning to realize that with the 
epidemic of prescription drug abuse and the high risk of dependency and abuse associated with 
newer, stronger drugs, that patient satisfaction and sound medical care are not always synonymous 
(Juurlink, Dhalla, & Nelson, 2011). 
 Although anyone could potentially be at risk of prescription drug dependence and abuse, it 
is important for health care providers to understand there are several groups who are at greater 
risk. These include: 
• Those who are on high daily doses of prescription painkillers, generally accepted to be 
above 120 milli-equivalents of morphine a day. 
• Lower-income individuals. 
• Those living in rural areas. 
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• Those receiving Medicaid, whose risk of death from an overdose of prescription painkillers 
is six times that of non-Medicaid individuals. 
• Males, whose rates exceed female rates in almost every age group. 
• Individuals between 45 and 54 years of age (CDC, 2011a). 
 It is often difficult for family medicine physicians to confidently discern between patients 
with a legitimate need for prescription painkillers and those with chemical-dependency issues or 
who simply want to experience the effects of the drug. Because 70% of Indiana’s family medicine 
residents will stay in Indiana after completing their residencies (Duwve, 2012), the training of 
these residents to address the problem of prescription drug abuse is a top priority. A number of 
Indiana’s 11 family medicine residency programs have already instituted training on the subject. 
This research project has looked primarily at the effects of such training instituted with the new 
residency year in 2010 at St. Vincent’s Family Medicine Residency (SVFMR) program due to 
their unique position of having readily-accessible data for analysis of residents’ prescribing habits. 
However, it should be noted that many of the other family medicine residency programs in Indiana 
are already addressing the problem of prescription drug abuse in one way or another. 
Research Questions 
 This research project has primarily addressed the following questions: 
1. What is the nature of the training and guidance on appropriate controlled-substance 
prescribing to which family medicine residents at SVFMR are currently being exposed? 
2. What effect has this training and guidance had on the prescribing habits of SVFMR 
residents? 
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3. What sort of guidance on appropriate controlled-substance prescribing is available 
elsewhere? 
4. What additional recommendations might be incorporated into the training and guidance on 
appropriate controlled-substance prescribing for family medicine residents at SVFMR and 
elsewhere? 
Methods 
 Because this project looked at the issue of training family medicine residents to address 
prescription drug abuse from an epidemiological perspective and from a health policy and 
management perspective, a wide range of information was collected. In addition to the information 
already discussed in the introduction of this paper, information was collected regarding the training 
and guidance provided on this issue to SVFMR residents over the course of the last several years, 
the training and guidance recommendations being put together by the Attorney General’s 
Prescription Drug Abuse Task Force, and the legislation currently occurring at the State level on 
this issue. 
 Information on SVFMR’s past, present, and upcoming resident training and guidance was 
obtained from the Family Medicine Clinic Co-Director, Amy LaHood, M.D., M.P.H., while data 
on residents’ prescribing patterns was obtained from the on-site pharmacy, at which a vast majority 
of patients fill their prescriptions. Both the family medicine clinic staffed by current SVFMR 
residents and the on-site pharmacy operate on a sliding fee scale which provides reduced rates for 
medical care and prescriptions to low-income patients. The vast majority of the family medicine 
clinic’s patients take advantage of this sliding fee scale, so it is assumed that most of the clinic’s 
Stephen M. Fielding 
Training Indiana’s Family Medicine Residents to Address the Problem of Prescription Drug Abuse 
8 | P a g e  
 
patients also fill their prescriptions at the on-site pharmacy, giving the data obtained from the 
pharmacy a great deal of internal validity. 
 Prescription information for all opioid painkillers and for alprazolam was obtained from a 
pharmacist at the on-site pharmacy, Wendy LeMasters, on a quarter-by-quarter basis from January 
1, 2009 (the beginning of 2008-2009 Quarter 3) to December 31, 2012 (the end of 2012-2013 
Quarter 2). The prescription data obtained from the pharmacy consisted of 13,897 prescriptions 
for opioids and for alprazolam filled during the time period under investigation. For these 
prescriptions, the following information was available: the quarter in which the prescription was 
written, the medication for which the prescription was written, the strength of the prescription in 
milligrams, the number of pills contained in the prescription, and the name of the provider writing 
the prescription. 
 Resident rosters were obtained from the Family Medicine Clinic Co-Director, and the 
names of all the family medicine residents active in the SVFMR program during the time period 
under investigation were recorded as in Table 1. First-year SVFMR residents attend orientation 
for the program at the end of June each year, and the residency year technically begins each July 
1. On July 1 of the next year, residents graduate to the next year of residency, for a total of three 
years. During the 2008-2009 residency year, there were 19 active SVFMR residents; during 2009-
2010, there were 22; during 2010-2011, there were 21; during 2011-2012, there were 22; during 
2012-2013, there were 22. The total number of family medicine residents active in the SVFMR 
program during the entire timeframe of the study was 50. This information is also displayed in 
Table 1. 
Table 1: Family Medicine Residents Active during the Timeframe of This Study  
Stephen M. Fielding 
Training Indiana’s Family Medicine Residents to Address the Problem of Prescription Drug Abuse 
9 | P a g e  
 
Prescriptions written by family medicine residents were abstracted from this data, and all 
opioid painkiller prescriptions were converted to a standardized scale making comparisons 
between different opioids more relevant. Prescription data was then analyzed using SAS 9.3 for 
Windows 64-bit machines using an α-level of 0.05 for significance. 
 Some information was unavailable for this analysis. This unavailable data included patient 
identifiers for each prescription and the number of pills a patient was directed to take each day. 
Because patient identifiers were unavailable with the prescription data obtained from the on-site 
pharmacy, it was impossible to determine either how many total patients were prescribed each of 
these medications during the timeframe of the study or to demonstrate the amount of time between 
refills for any particular patient. Without knowing the number of pills a patient was directed to 
take each day, it remained impossible to determine what sort of daily dose each patient was on. 
To aid in the comparison of dosages of different types of opioids to each other, physicians 
routinely make use of a measure called morphine milli-equivalents. Therefore, in order to find 
some meaning from the data that was available, each prescription was converted to a total number 
of milli-equivalents of morphine (mEq’s) using the guidelines in place at SVFMR in the following 
manner. The strength of hydrocodone prescriptions in milligrams were multiplied by 1 to obtain 
the strength in morphine milli-equivalents. The strength of methadone prescriptions were 
multiplied by 4, the strength of morphine prescriptions were multiplied by 1, the strength of 
oxycodone prescriptions were multiplied by 1.5, and the strength of percocet prescriptions were 
multiplied by 1.5 as well. 
Because information on the number of pills each patient was directed to take each day was 
unavailable, the assumption was made that prescribing patterns have not changed on average in 
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this regard during the timeframe of the study. This assumption allowed prescriptions to be 
compared on the basis of total number of milli-equivalents prescribed. For example, a prescription 
for 90, 40 mg pills of oxycodone was converted to 90 x 40 x 1.5 = a prescription of 5,400 mEq. 
Alprazolam was included in this study not as a control, but because it, too, is a controlled 
substance which falls under the training and guidance family medicine residents at SVFMR 
receive. However, alprazolam is a benzodiazepine anxiolytic drug, not an opioid. Therefore, the 
strengths of alprazolam prescriptions were compared on the basis of total mg, not total mEq. 
Lastly, patient volume information was collected for each of the clinics housed in St. 
Vincent’s Max Simon Primary Care Center. The Primary Care Center includes the family medicine 
clinic and the on-site pharmacy, as well as an internal medicine clinic, a pediatrics clinic, and a 
women’s health clinic. Patient volume data was abstracted for each quarter pertaining to the 
timeframe of this study for the family medicine clinic. 
Data 
Training and Guidance at the St. Vincent Family Medicine Residency Program 
 Up until the beginning of the new residency year in July 2010, family medicine residents 
had been advised to use their best clinical judgment in caring for patients requiring controlled 
substances. Without passing judgment on how residents had been approaching these patients 
before this time period, SVFMR residents began receiving training on a robust set of guidelines 
regarding appropriate prescribing practices for these patients in July 2010. The protocol on 
appropriate controlled substances prescribing is outlined below: 
Stephen M. Fielding 
Training Indiana’s Family Medicine Residents to Address the Problem of Prescription Drug Abuse 
11 | P a g e  
 
• Residents should not prescribe controlled substances to a patient at their initial consultation 
at the family medicine clinic if there is not sufficient and appropriate documentation from 
a previous provider substantiating the need for these medications. 
• Residents should request a report from INSPECT on all patients at their initial consultation 
and before making any changes to their treatment plan. 
• Residents should consult with an attending physician before prescribing a controlled 
substance, whether the prescription is the first or a refill. 
• Residents should have any patient who will be prescribed controlled substances for greater 
than one month sign a controlled substance contract. The contract functions as a treatment 
agreement between the resident and the patient, and describes what will be expected from 
a patient who is prescribed controlled substances for a significant length of time. For 
example, the patient must agree to be seen by the physician periodically and submit to 
periodic urine drug screens. 
• Residents should see any patients on controlled substances on a monthly basis until such a 
time as their condition is deemed stable, and every three months thereafter. 
• Residents should conduct urine drug testing at least once a year for all patients taking 
controlled substances, and more often if there is any suspicion of additional drug use, 
prescription or otherwise, or of drug diversion. 
• Residents should have patients bring all their prescriptions to each appointment so that they 
may be counted to detect possible drug misuse or diversion. 
In May 2013, after the conclusion of this study, the SVFMR program’s guidelines evolved 
further to include some more-recently-accepted best practices on prescribing controlled 
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substances. Some highlights of the additions and changes to SVFMR’s guidelines put in place this 
year are outlined below: 
• Residents are required to perform their own detailed medical history and physical exam on 
new patients in addition to reviewing previous medical records. 
• Residents should measure the risk of substance abuse for each chronic pain patient using 
mental health metrics such as PHQ-2© or PHQ-9© (for depression) and GAD-7© (for 
anxiety) and addiction risk assessments such as the Opioid Risk Tool©, SOAPP©, or 
COMM©. Residents are strongly discouraged from prescribing controlled substances to 
any individual which is deemed to be high-risk. Additionally, such assessments should be 
conducted periodically as risk levels may change over time. 
• Residents should set goals with patients that focus more on functions of daily living than 
on symptom relief. Oftentimes, a medication will not completely alleviate a symptom no 
matter what the dose, but even a low dose may allow the patient to get back to living their 
life the way they want to. Setting reasonable goals at the outset of a treatment plan will 
often lead to better outcomes and higher patient satisfaction. 
• Residents should make use of non-opioid treatments initially, when possible. 
• Residents may not prescribe more than a combined 100 mEq per day of opioid medications. 
• Residents may not initiate a new treatment regimen that includes methadone. 
• Residents may not prescribe short-acting benzodiazepines (e.g. for anxiety) for greater than 
one month. 
Indiana Senate Enrolled Act No. 246 – Controlled Substances 
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 Indiana Senate Bill 246, authored by State Senator Ron Grooms from District 46, was 
introduced on January 7, 2013 and signed into law by Governor Mike Pence on May 7, 2013, 
taking effect shortly thereafter as Public Law 185. The controlled substances portion of this 
legislation authorizes Indiana’s Medical Licensing Board to adopt emergency rules before 
November 1, 2013 to address physician responsibilities regarding the prescribing of controlled 
substances in the State. Permanent rules must then be adopted by the Medical Licensing Board 
before November 1, 2013. These rules remain to be seen. However, the Medical Licensing Board 
is taking input from the Indiana Attorney General’s Prescription Drug Abuse Task Force in the 
formation of these rules. 
Provider Toolkit under Development by the Prescription Drug Abuse Task Force 
 Prior to the introduction of Senate Bill 246, the Education Committee of the Prescription 
Drug Abuse Task Force began developing a “Provider Toolkit” with input from health care 
providers from all corners of the State to provide a set of best practices to help guide providers as 
they work toward more sound management of patients with chronic non-cancer pain. The toolkit, 
entitled “First Do No Harm – The Indiana Health Care Providers Guide to the Safe, Effective 
Management of Chronic Non-Cancer Pain” has continued to be developed in collaboration with 
the Medical Licensing Board of Indiana. As a note, I was fortunate that through my internship 
experience at the Indiana State Department of Health I was able to attend several meetings of the 
Prescription Drug Abuse Task Force and had a good amount of input into the introduction portion 
of the Provider Toolkit. 
St. Vincent Family Medicine Residency Program Resident Prescription Data 
Stephen M. Fielding 
Training Indiana’s Family Medicine Residents to Address the Problem of Prescription Drug Abuse 
14 | P a g e  
 
During the time period under study, SVFMR residents wrote a total of 1,909 prescriptions 
for opioid painkillers and an additional 127 prescriptions for alprazolam. Table 2 outlines for 
which medications these prescriptions were written, and shows the corresponding total number of 
patient visits during each time period. 
Results 
 The data set was first broken into quarters so that the same quarters could be compared in 
a year-over-year fashion. In order to determine the statistical tests needed to compare quarters to 
each other for the entire data set and for each medication type, each group in the data set was tested 
for the presence of a normal distribution using the Shapiro-Wilk test as shown in Table 3. 
Next, the tests needed for comparison of the groups were determined in light of the previous 
normality results as shown in Table 4. The quarterly year-over-year comparisons of the data 
revealed several significant differences between the same quarters in different years for opioid 
painkillers in general and for a number of medication types in particular. The significant results 
are shown in Table 5. Any significant differences that include time periods after resident training 
began at the start of the 2010-2011 residency year are shown in red. 
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Table 2: Number of Prescriptions Broken down by Medication Type and Time Period  
Stephen M. Fielding 
Training Indiana’s Family Medicine Residents to Address the Problem of Prescription Drug Abuse 
16 | P a g e  
 
Table 3: Results of Shapiro-Wilk Tests for Normality  
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Table 4: Tests Used for Comparison of Groups  
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Table 5: Comparisons Showing Significant Differences  
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Limitations 
 This study has a number of limitations: 
 Firstly, the pharmacy data did not include patient identifiers. Each data entry included only 
information on the time period of the prescription, the medication type, the number of mg of each 
pill, the number of pills dispensed, and the provider. If patient identifiers were available in this 
data set, further analysis could be conducted to determine the effects of increased resident training 
on the subject of prescription drug abuse and appropriate prescribing. Specifically, the amount of 
controlled substances each individual patient receives during any particular time period could have 
been calculated. Furthermore, any trends in the number of patients receiving the controlled 
substances under study could have been compared to trends in patient volumes during those time 
periods. 
 Secondly, the providers instructions regarding how many pills should be taken a day were 
unavailable. Therefore, a 30-pill prescription and a 90-pill prescription, for example, could not be 
discerned from each other on the basis of how many pills the patient was directed to take a day. 
To handle this limitation, the assumption was made that residents’ prescribing habits, on the whole, 
have remained unchanged in this regard. 
 Thirdly, the data used for this analysis came from the on-site pharmacy at which a vast 
majority of SVFMR’s patients fill their prescriptions. The exact proportion of patients filling their 
prescriptions at the on-site pharmacy was unknown. Furthermore, it was unknown how the patients 
that filled their prescriptions at this pharmacy compared to the relatively few patients who fill their 
prescriptions elsewhere. Two assumptions were made in this regard: 1) the vast majority of patients 
of the SVFMR family clinic fill their prescriptions at the on-site pharmacy, and 2) the 
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characteristics of these patients are the same as for those who fill their prescriptions elsewhere. 
The first assumption has been validated anecdotally, and makes sense in light of the fact that both 
the clinic and the pharmacy operate on a sliding fee scale and that most patients of the clinic utilize 
these reduced rates. 
 Lastly, it is unclear how the proportion of patients being treated for chronic pain at St. 
Vincent’s family medicine clinic has changed over the last several years. For the purposes of this 
study, it has been assumed that the number of legitimate pain patients relative to the total patient 
volume has not changed. 
 In a future study of this kind, the first three limitations could be best addressed by obtaining 
the prescription data from INSPECT, Indiana’s prescription drug monitoring program, rather than 
from an individual pharmacy. This, however, would require consent from the providers whose 
prescription data is being looked at, but could likely be obtained in such a way that patient names 
and identifiable information are omitted. Either way, institutional review board (IRB) approval 
would be needed. The last limitation could be addressed by obtaining a large enough random 
sample of patient charts from each time period under investigation and calculating the proportion 
of patients being treated for chronic pain. 
Conclusions 
 The resident training and guidance on appropriate controlled-substance prescribing at St. 
Vincent’s Family Medicine Residency program, instituted with the start of the new residency year 
2010-2011, has shown signs of successes. Assuming that the number of days for which each 
prescription was intended did not change on average, the amount of opioid painkillers being 
prescribed at a time decreased significantly during the 3rd quarter of 2011-2012. Particularly, there 
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was significant progress in reducing the amount of hydrocodone and alprazolam written at one 
time for several of the quarters included in the study. However, this trend did not extend to 
oxycodone or methadone. There were significant increases in the amount of these drugs being 
prescribed at one time. 
 It is reassuring to see that the raw numbers of prescriptions written for each type of 
controlled substance under study decreased over the last couple years even while patient volumes 
remained relatively steady. Although the data set used for this investigation did not allow for a 
more thorough investigation of the statistical significance of this decline, it appears that SVFMR 
residents are embracing the idea that medications such as opioid painkillers are only one of many 
treatment options to consider. 
There has been significant improvement in reducing the amount of opioids and alprazolam 
being prescribed, and consistent application of these guidelines at SVFMR, along with continued 
evolution of the training and guidance recommendations, will likely result in further successes. 
From a public health perspective, this can only be a good thing for Indiana. Given that so many of 
Indiana’s family medicine residents stay in the Hoosier State to practice following the conclusion 
of their residencies, training and guidance on appropriate controlled substance prescribing 
practices will contribute a great deal to the health and wellbeing of the entire State. 
Recommendations 
 Recommendations coming out of this project fall into two categories: recommendations 
for family medicine residency programs, and recommendations for future studies of this kind. 
For Family Medicine Residency Programs 
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For family medicine residency programs, it is recommended to provide guidance and 
training to residents on par with what the SVFMR has provided in the most recent evolution of its 
controlled substance prescribing guidelines. Many of Indiana’s family medicine residency 
programs already have similar guidelines, and these would be recommended for those who are still 
looking for a way to systematically address the problem of prescription drug abuse. 
At the outset of this project, it was expected that training and guidance materials would be 
created and endorsed by the Indiana State Department of Health for distribution to Indiana’s 11 
family medicine residency programs in order to give them a place to start in developing guidelines 
that made sense for their organizations. However, with the more recent development of the 
Provider Toolkit being produced by the Education Committee of the Attorney General’s 
Prescription Drug Abuse Task Force, and the signing into Law of Public Law 185, it is now 
recommended that Indiana’s family medicine residency programs endorse and promote these sets 
of best practices for their organizations. Through collaboration with the groups responsible for the 
production of the Toolkit and the writing of the rules for the Medical Licensing Board, it appears 
that these will both be in line with the most current evolution of SVFMR’s training and guidance. 
The SVFMR guidelines do go a step further than what these best practices do in regards to the 
maximum daily dose allowed to be prescribed by a resident in training. SVFMR’s guidelines state 
that a resident may not prescribe more than 100 mEq per day of opioid painkillers due to the 
increased risk of death associated with higher daily dosages. While this research does not provide 
evidence backing up any particular maximum daily dosage, it would be prudent for family 
medicine residency programs to consider instituting a maximum daily dosage themselves. 
For Future Studies of This Kind  
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For future studies of this kind, it is recommended to utilize INSPECT, Indiana’s 
prescription drug monitoring program, as one primary source of data. The data obtained for this 
study likely captured most of SVFMR’s pain patients, but other residency programs may not have 
such a readily-available, in-house, source of data. Also, the use of patient identifiers for each 
prescription, as well as information on the number of pills directed to be taken a day, would allow 
a much more thorough investigation of the effects of any change in training and guidance provided 
to residents. 
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